Proteins for Coronavirus Research
Coronavirus Proteins
Omicron Spike Proteins – Now Available!
The omicron variant has become the dominant SARS-CoV-2 strain worldwide. R&D Systems is proud to offer bioactive, stable, and consistent omicron variant Spike proteins to help speed discovery and therapeutic development.
Fluorokines™ for COVID-19 Research
Check out our new Fluorokines fluorescent-labeled Spike proteins featuring Alexa Fluor Dyes. Easily detect ACE-2 expression on cells without the need for a secondary detection step. Explore Our FluorokinesTM Fluorescent-labeled Recombinant Proteins.
R&D Systems offers a range of SARS-CoV-2 proteins and other Coronavirus proteins with the same industry-leading quality specifications as our other recombinant proteins. Our SARS-CoV-2 Spike proteins exhibit high affinity binding to human ACE-2 in both ELISA and SPR. And the Coronavirus proteases, Papain-like Protease and 3CL protease, are tested for bioactivity using biologically relevant fluorescent substrates. For more detailed information about our recombinant Coronavirus proteins, visit the product pages listed below.
View frequently asked questions about our coronavirus proteins.
Spike Protein Ectodomain S1+S2 | |||||
|---|---|---|---|---|---|
| Protein | Coronavirus Type | Source | Tag | Catalog # | Bioactivity |
| Spike Protein | SARS-CoV-2 | HEK293 | His | 10549-CV | Binds ACE-2 (Catalog # 933-ZN) |
| SARS-CoV-2 | CHO | His | 10586-CV | ||
| SARS-CoV | HEK293 | His | 10683-CV | ||
| Bat CoV | CHO | His | 10660-CV | ||
| Spike Protein Full Length 16-1273 | SARS-CoV-2 | HEK293 | 11058-CV | Binds ACE-2 (Catalog # 933-ZN) | |
| Spike Protein Biotinylated | SARS-CoV-2 | HEK293 | His, Biotin | BT10549 | Binds ACE-2 (Catalog # 10544-ZN) |
| CHO | His, Avi-tag | AVI10586 | |||
| HEK293 | GCN4-IZ, His, Avi-tag | AVI10561 | |||
| Spike Protein + GCN4-IZ | SARS-CoV-2 WT | HEK293 | GCN4-IZ, His | 11110-CV | Binds Neuropilin-1 (Catalog # 10455-N1) |
| SARS-CoV-2 R682S, R685S, K986P, V987P | HEK293 | GCN4-IZ, His | 10561-CV | Binds ACE-2 (Catalog # 933-ZN) | |
| SARS-CoV-2 R682S, R685S, K986P, V987P | CHO | GCN4-IZ, His | 10638-CV | ||
| SARS-CoV | HEK293 | GCN4-IZ, His | 10684-CV | ||
| SARS-CoV | CHO | GCN4-IZ, His | 10581-CV | ||
| MERS-CoV | HEK293 | GCN4-IZ, His | 10739-CV | Binds DPPIV/CD26 (Catalog # 9168-SE) | |
| Bat CoV | HEK293 | GCN4-IZ, His | 10688-CV | Binds ACE-2 (Catalog # 10544-ZN) | |
| Alexa Fluor® Spike Protein + GCN4-IZ | SARS-CoV-2 | HEK293 | GCN4-IZ, His, Alexa Fluor® 488 | AFG10561 | Binds ACE-2 in flow cytometry |
| GCN4-IZ, His, Alexa Fluor® 647 | AFR10561 | ||||
Spike Protein S1 Subunit | |||||
|---|---|---|---|---|---|
| Protein | Coronavirus Type | Source | Tag | Catalog # | Bioactivity |
| Spike S1 Protein | SARS-CoV-2 | HEK293 | His | 10569-CV | Binds ACE-2 (Catalog # 933-ZN) |
| SARS-CoV-2 | CHO | His | 10693-CV | ||
| SARS-CoV-2 | Sf21 | His | 10522-CV | ||
| SARS-CoV-2 | Tn5 | Fc | 10622-CV | ||
| SARS-CoV-2 | CHO | Fc | 10623-CV | ||
| SARS-CoV | HEK293 | His | 10783-CV | ||
| SARS-CoV | CHO | His | 10745-CV | ||
| SARS-CoV | Sf21 | His | 10570-CV | ||
| SARS-CoV | HEK293 | Fc | 10685-CV | ||
| SARS-CoV | CHO | Fc | 10782-CV | ||
| MERS-CoV | HEK293 | His, GCN4 | 10737-CV | Binds human DPPIV/CD26 (Catalog # 9168-CV) | |
| MERS-CoV | CHO | Fc | 10606-CV | ||
| Bat CoV | CHO | His | 10662-CV | Binds ACE-2 (Catalog # 10544-ZN) | |
| Bat CoV | HEK293 | His, GCN4 | 10661-CV | ||
| Spike S1 Protein biotinylated | SARS-CoV-2 | HEK293 | His | BT10569 | Binds ACE-2 (Catalog # 10544-ZN) |
| SARS-CoV-2 | CHO | His, Avi-tag | AVI10693 | ||
| Spike Protein S1 NTD | SARS-CoV-2 | HEK293 | His | 11112-CV | |
| Spike S1 + HR1/HR2 Fusion | SARS-CoV-2 | CHO | His | 10687-CV | Binds ACE-2 (Catalog # 933-ZN) |
Spike Protein S2 Subunit | |||||
|---|---|---|---|---|---|
| Protein | Coronavirus Type | Source | Tag | Catalog # | Bioactivity |
| SARS-CoV-2 Spike S2 Subunit | SARS-CoV-2 | HEK293 | His | 10594-CV | |
| SARS-CoV-2 | Tn5 | His | 10584-CV | ||
| SARS-CoV-2 | HEK293 | His | 10639-CV | ||
| SARS-CoV-2 Spike S2 Subunit (GCN4-IZ) | SARS-CoV-2 | HEK293 | His | 10590-CV | |
| SARS-CoV-2 | HEK293 | His | 10640-CV | ||
SARS-CoV-2 Spike Protein Variants
SARS-CoV-2 Variant Inhibitor Screening Kit – Now Available!
Easy to use ELISA assay to measure neutralizing activity in serum/plasma. Includes wild-type Spike RBD protein and mutant Spike RBD proteins from Alpha, Beta, Gamma, and Delta variants. Test samples against 5 Spike proteins in a single kit. Order SARS-CoV-2 Variant Inhibitor Screening Kit Now!
Omicron Variant B.1.1.529 | |||
|---|---|---|---|
| Spike Protein | Description | Tag | Catalog # |
| Spike Protein | Omicron variant B.1.1.529 | His | 11060-CV |
| GCN4-IZ, His | 11061-CV | ||
| His, Avi-tag | AVI11060 | ||
| GCN4-IZ, His, Avi-tag | AVI11061 | ||
| His, Biotinylated | BT11060 | ||
| GCN4-IZ, His, Biotinylated | BT11061 | ||
| His, Alexa Fluor® 488 | AFG11060 | ||
| His, Alexa Fluor® 647 | AFR11060 | ||
| GCN4-IZ, His, Alexa Fluor® 488 | AFG11061 | ||
| GCN4-IZ, His, Alexa Fluor® 647 | AFR11061 | ||
| Omicron variant BA.2 | GCN4-IZ, His | 11109-CV | |
| GCN4-IZ, His, Avi-tag | AVI11109 | ||
| GCN4-IZ, His, Biotinylated | BT11109 | ||
| GCN4-IZ, His, Alexa Fluor® 488 | AFG11109 | ||
| GCN4-IZ, His, Alexa Fluor® 647 | AFR11109 | ||
| Omicron variant BA.2.12.1 | GCN4-IZ, His | 11287-CV | |
| Omicron variant BA.2.75 | GCN4-IZ, His | 11260-CV | |
| Omicron variant BA.2.86 | GCN4-IZ, His | 11478-CV | |
| Omicron variant BA.4/BA.5 | His | 11232-CV | |
| GCN4-IZ, His | 11231-CV | ||
| GCN4-IZ, His, Alexa Fluor® 488 | AFG11231 | ||
| GCN4-IZ, His, Alexa Fluor® 647 | AFR11231 | ||
| Omicron variant BA.4.6 | GCN4-IZ, His | 11286-CV | |
| Omicron variant BQ.1.1 | GCN4-IZ, His | 11359-CV | |
| Omicron variant EG.5.1 | GCN4-IZ, His | 11451-CV | |
| Omicron variant XBB.1 | GCN4-IZ, His | 11371-CV | |
| Omicron variant XBB.1.5 | GCN4-IZ, His | 11372-CV | |
| Omicron variant XD | GCN4-IZ, His | 11321-CV | |
| Spike Protein RBD | Omicron variant B.1.1.529 | His | 11056-CV |
| Fc | 11057-CV | ||
| His, Avi-tag | AVI11056 | ||
| His, Biotinylated | BT11056 | ||
| His, Alexa Fluor® 488 | AFG11056 | ||
| His, Alexa Fluor® 647 | AFR11056 | ||
| Omicron variant BA.1.1 | His | 11131-CV | |
| Omicron variant BA.2 | His | 11094-CV | |
| His, Avi-tag | AVI11094 | ||
| His, Biotinylated | BT11094 | ||
| Fc | 11148-CV | ||
| His, Alexa Fluor® 488 | AFG11094 | ||
| His, Alexa Fluor® 647 | AFR11094 | ||
| Omicron variant BA.2.75 | His | 11259-CV | |
| Omicron variant BA.2.86 | His | 11440-CV | |
| Omicron variant BA.4/BA.5 | His | 11229-CV | |
| His, Alexa Fluor® 488 | AFG11229 | ||
| His, Alexa Fluor® 647 | AFR11229 | ||
| Omicron variant BA.4.6 | His | 11283-CV | |
| Omicron variant BQ.1.1 | His | 11322-CV | |
| Omicron variant EG.5.1 | His | 11442-CV | |
| Omicron variant XBB.1 | His | 11330-CV | |
| Omicron variant XBB.1.5 | His | 11360-CV | |
| Spike Protein S1 | Omicron variant B.1.1.529 | His | 11070-CV |
| GCN4-IZ, His | Preorder | ||
| Omicron variant BA.2 | His | 11149-CV | |
| Omicron variant BA.4/BA.5 | His | 11184-CV | |
| XD variant: Omicron/Delta hybrid | His | 11219-CV | |
| Spike Protein S1 NTD | Omicron variant B.1.1.529 | His | 11104-CV |
| Omicron variant BA.2 | His | 11147-CV | |
| Omicron variant BA.4/BA.5 | His | 11183-CV | |
| XD variant: Omicron/Delta hybrid | His | 11208-CV | |
| Spike Protein S2 | Omicron variant B.1.1.529 | His | Preorder |
| SARS-CoV-2 Nucleocapsid Protein | Omicron variant B.1.1.529 | His | 11099-CV |
| Omicron variant BA.2 | His | 11182-CV | |
IHU Variant B.1.640.2 | ||||
|---|---|---|---|---|
| Spike Protein | Description | Source | Tag | Catalog # |
| Spike Protein | IHU variant B.1.640.2 | HEK293 | GCN4-IZ, His | 11105-CV |
| Spike Protein RBD | IHU variant R346S, N394S, Y449N, E484K, F490S, N501Y | HEK293 | His | 11097-CV |
Delta Variant B.1.617.2 (India) | ||||
|---|---|---|---|---|
| Spike Protein | Description | Source | Tag | Catalog # |
| Spike Protein | Delta variant B.1.617.2 T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950N | HEK293 | His | 10942-CV |
| Spike Protein | Delta variant B.1.617.2 T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950N | HEK293 | GCN4-IZ, His | 10878-CV |
| Spike Protein | Delta variant B.1.617.2 T19R, G142D, Y144del, E156G, F157del, R158del, A222V, L452R, T478K, D614G, P681R, D950N | HEK293 | GCN4-IZ, His | 10924-CV |
| Spike Protein Biotinylated | Delta variant B.1.617.2 T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950N | HEK293 | GCN4-IZ, His, Avi-tag | AVI10878 |
| Alexa Fluor® Spike Protein | Delta variant B.1.617.2 T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950N | HEK293 | Alexa Fluor® 488, GCN4-IZ, His | AFG10878 |
| Alexa Fluor® 647, GCN4-IZ, His | AFR10878 | |||
| Spike Protein | Delta Plus AY.1 T19R, T95I, G142D, E156G, F157del, R158del, W258L, K417N, L452R, T478K, D614G, P681R, D950N | HEK293 | GCN4-IZ, His | 10922-CV |
| Spike Protein | Delta Plus AY.2 T19R, V70F, G142D, E156G, F157del, R158del, R222V, K417N, L452R, T478K, D614G, P681R, D950N | HEK293 | GCN4-IZ, His | 10923-CV |
| Spike RBD | Delta variant B.1.617.2 L452R, T478K | HEK293 | His | 10876-CV |
| Alexa Fluor® 488, His | AFG10876 | |||
| Alexa Fluor® 647, His | AFR10876 | |||
| Fc | 10901-CV | |||
| His, Avi-tag | AVI10876 | |||
| Spike RBD | Delta variant B.1.617.2 G446V, L452R, T478K | HEK293 | His | 10982-CV |
| His, Avi-tag | AVI10982 | |||
| Spike RBD | Delta Plus AY.1/AY.2 K417N, L452R, T478K | HEK293 | His | 10905-CV |
| Fc | 10908-CV | |||
| Spike RBD | G446V, L452R, T478K | HEK293 | Fc | 10983-CV |
| Spike RBD | T478K | HEK293 | His | 10875-CV |
| Spike Protein S1 | Delta variant B.1.617.2 T19R, G142D, E156G, F157del, R158del, L452R, T478K, D614G, P681R | HEK293 | His | 11132-CV |
| Spike Protein S1 NTD | Delta variant B.1.617.2 T19R, G142D, E156G, F157del, R158del | HEK293 | His | 11114-CV |
Alpha Variant B.1.1.7 (UK) | ||||
|---|---|---|---|---|
| Spike Protein | Description | Source | Tag | Catalog # |
| Spike Protein | Alpha variant B.1.1.7 H69del, V70del, Y145del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H | HEK293 | His GCN4-IZ, His | 10748-CV |
| 10796-CV | ||||
| Spike Protein Biotinylated | Alpha variant B.1.1.7 H69del, V70del, Y145del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H | HEK293 | GCN4-IZ, His, Biotin | BT10796 |
| GCN4-IZ, His, Avi-tag | AVI10796 | |||
| Alexa Fluor® Spike Protein | Alpha variant B.1.1.7 | HEK293 | Alexa 488, GCN4-IZ, His | AFG10796 |
| H69del, V70del, Y145del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H | Alexa 647, GCN4-IZ, His | AFR10796 | ||
| Spike Protein | Alpha variant B.1.1.7 + E484K | HEK293 | GCN4-IZ, His | 10824-CV |
| Spike Protein | Alpha variant B.1.1.7 + S494P | HEK293 | GCN4-IZ, His | 10854-CV |
| Spike RBD | N501Y (Alpha, Beta, Gamma) | HEK293 | His | 10730-CV |
| His, Biotin | BT10730 | |||
| E484K, N501Y | HEK293 | His | 10788-CV | |
| Spike RBD Biotinylated | N501Y (Alpha, Beta, Gamma) | HEK293 | His, Avi-tag | AVI10730 |
| Spike Protein S1 | Alpha variant B.1.1.7 H69del, V70del, Y145del, N501Y, A570D, D614G, P681H | HEK293 | His | 11137-CV |
| Spike Protein S1 NTD | Alpha variant B.1.1.7 H69del, V70del, Y145del | HEK293 | His | 11115-CV |
Beta Variant B.1.351 (South Africa) | |||||
|---|---|---|---|---|---|
| Spike Protein | Description | Source | Tag | Catalog # | |
| Spike Protein | Beta variant B.1.351 D80A, D215G, L242del, A243del, L244del, K417N, E484K, N501Y, D614G, A701V | HEK293 | His | 10777-CV | |
| HEK293 | GCN4-IZ, His | 10786-CV | |||
| Alexa Fluor® Spike Protein | Beta variant B.1.351 D80A, D215G, L242del, A243del, L244del, K417N, E484K, N501Y, D614G, A701V | HEK293 | Alexa 488, GCN4-IZ, His | AFG10786 | |
| Alexa 647, GCN4-IZ, His | AFR10786 | ||||
| Spike Protein | Beta variant B.1.351 + L18F D80A, D215G, L242del, A243del, L244del, K417N, E484K, N501Y, D614G, A701V | HEK293 | GCN4-IZ, His | 10785-CV | |
| Spike Protein Biotinylated | Beta variant B.1.351 + L18F D80A, D215G, L242del, A243del, L244del, K417N, E484K, N501Y, D614G, A701V | HEK293 | GCN4-IZ, His, Avi-tag | AVI10785 | |
| Spike RBD | Beta variant B.1.351 K417N, E484K, N501Y | HEK293 | His | 10735-CV | |
| HEK293 | Fc | 10935-CV | |||
| N501Y (Alpha, Beta, Gamma) | HEK293 | His | 10730-CV | ||
| HEK293 | Fc | 10717-CV | |||
| E484K, N501Y | HEK293 | His | 10788-CV | ||
| E484K | HEK293 | His | 10747-CV | ||
| Spike RBD Biotinylated | Beta variant B.1.351 K417N, E484K, N501Y | HEK293 | His, Avi-tag |
| |
| Spike Protein S1 | Beta variant B.1.351 L18F, D80A, D215G, L242del, A243del, L244del, K417N, E484K, N501Y, D614G | HEK293 | His | 11133-CV | |
| Spike Protein S1 NTD | Beta variant B.1.351 L18F, D80A, D215G, L242del, A243del, L244del | HEK293 | His | 11113-CV | |
Gamma Variant P.1 (Brazil) | ||||
|---|---|---|---|---|
| Spike Protein | Description | Source | Tag | Catalog # |
| Spike Protein | Gamma Variant P.1 L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F | HEK293 | GCN4-IZ, His | 10795-CV |
| Spike Protein Biotinylated | Gamma Variant P.1 L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F | HEK293 | GCN4-IZ, His, Avi-tag | AVI10795 |
| Alexa Fluor® Spike Protein | Gamma Variant P.1 L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F | HEK293 | Alexa Fluor® 488, GCN4-IZ, His | AFG10795 |
| Alexa Fluor® 647, GCN4-IZ, His | AFR10795 | |||
| Spike RBD | Gamma Variant P.1 K417T, E484K, N501Y | HEK293 | His | 10775-CV |
| Fc | 10914-CV | |||
| N501Y (Alpha, Beta, Gamma) | HEK293 | His | 10730-CV | |
| HEK293 | Fc | 10717-CV | ||
| E484K, N501Y | HEK293 | His | 10788-CV | |
| E484K | HEK293 | His | 10747-CV | |
| Spike Protein S1 | Gamma Variant P.1 L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y | HEK293 | His | 11138-CV |
| Spike Protein S1 NTD | Gamma variant P.1 L18F, T20N, P26S, D138Y, R190S | HEK293 | His | 11111-CV |
Kappa Variant B.1.617.1 (India) | ||||
|---|---|---|---|---|
| Spike Protein | Description | Source | Tag | Catalog # |
| Spike Protein | Kappa variant B.1.617.1 G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H | HEK293 | His | 10978-CV |
| Spike Protein | Kappa variant B.1.617.1 G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H | HEK293 | GCN4-IZ, His | 10861-CV |
| Alexa Fluor® Spike Protein | Kappa variant B.1.617.1 G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H | HEK293 | Alexa 488, GCN4-IZ, His | AFG10861 |
| Alexa 647, GCN4-IZ, His | AFR10861 | |||
| Spike RBD | Kappa variant B.1.617.1 L452R, E484Q | HEK293 | His | 10846-CV |
| Fc | 10906-CV | |||
| Spike RBD Biotinylated | Kappa variant B.1.617.1 L452R, E484Q | HEK293 | His, Avi-tag | AVI10846 |
Other Notable Spike Protein Mutants | ||||
|---|---|---|---|---|
| Spike Protein | Description | Source | Tag | Catalog # |
| Spike Protein | D614G | HEK293 | GCN4-IZ, His | 10853-CV |
| HEK293 | His | 10587-CV | ||
| CHO | His | 10620-CV | ||
| Spike Protein | 20C-US variant D614G, Q677H | HEK293 | His | 10769-CV |
| Spike Protein | A.27 L18F, L452R, N501Y, A653V, H655Y, D796Y | HEK293 | GCN4-IZ, His | 10845-CV |
| Spike Protein | A.23.1 R102I, F157L, V367F, E484K, Q613H, P681R | HEK293 | GCN4-IZ, His | 10860-CV |
| Spike Protein | AV.1 D80G, T95I, G142D, Y144del, N439K, E484K, D614G, P681H, I1130V, D1139H | HEK293 | GCN4-IZ, His | 10896-CV |
| Spike Protein | AY.4.2 T19R, T95I, G142D, Y145H, E156G, F157del, R158del, A222V, L452R, T478K, D614G, P681R, D950N | HEK293 | GCN4-IZ, His | 11065-CV |
| Spike Protein | B.1.1.318 T95I, Y144del, E484K, D614G, P681H, D796H | HEK293 | GCN4-IZ, His | 10856-CV |
| Spike Protein | B.1.1.519 T478K, D614G, P681H, T732A | HEK293 | GCN4-IZ, His | 10883-CV |
| Spike Protein | Eta Variant B.1.525 Q52R, A67V, H69del, V70del, Y145del, E484K, D614G, Q677H, F888L | HEK293 | GCN4-IZ, His | 10794-CV |
| Spike Protein | Iota Variant B.1.526 D253G, E484K, D614G, A701V | HEK293 | GCN4-IZ, His | 10848-CV |
| Spike Protein | B.1.526.1 D80G, Y144del, F157S, L452R, D614G, T791I, T859N, D950H | HEK293 | GCN4-IZ, His | 10895-CV |
| Spike Protein | B.1.526.2 D253G, S477N, D614G, Q957R | HEK293 | GCN4-IZ, His | 10874-CV |
| Spike Protein | B.1.616 H66D, G142V, Y144del, D215G, V483A, D614G, H655Y, G669S, Q949R, N1187D | HEK293 | GCN4-IZ, His | 10933-CV |
| Spike Protein | B.1.620 P26S, His69del, V70del, V126A, Y144del, K242del, A243del, K244del, H245Y, S477N, E484K, D614G, P681H, T1027I, D1118H | HEK293 | GCN4-IZ, His | 10917-CV |
| Spike Protein | B.1.630 C136F, Y144del, A222V, A243del, L244del, L452R, T478R, E484Q, D614G, H655T, D950N | HEK293 | GCN4-IZ, His | 11071-CV |
| Spike Protein | B.1.640 E96Q, C136del-Y144del, R190S, I210T, R346S, N394S, Y449N, F490R, N501Y, D614G, P681H, T859N, D936H | HEK293 | GCN4-IZ, His | 11076-CV |
| Spike Protein | C.1.2 P25L, C136F, Y144del, R190S, D215G, A243del, L244del, Y449H, E484K, N501Y, L585F, D614G, H655Y, D679K, T716I, T859N | HEK293 | GCN4-IZ, His | 11007-CV |
| Spike Protein | C.36.3 H69del, V70del, W152R, R346S, L452R, D614G, Q677H, A899S, R682S, R685S, K986P, V987P | HEK293 | GCN4-IZ, His | 10886-CV |
| Spike Protein | Lambda Variant C.37 G75V, T76I, RSYLTPG246-252del, D253N, L452Q, F490S, D614G, T859N | HEK293 | GCN4-IZ, His | 10887-CV |
| GCN4-IZ, His, Avi-tag | AVI10887 | |||
| Spike Protein | Mu Variant B.1.621 T95I, Y144T, Y145S, ins145N, R346K, E484K, N501Y, D614G, P681H, D950N | HEK293 | GCN4-IZ, His | 10899-CV |
| Spike Protein | CAL.20C W152C, L452R, D614G | HEK293 | GCN4-IZ, His | 10849-CV |
| Spike Protein | Mink Cluster-5 variant H69del, V70del, Y453F, D614G, I692V | HEK293 | His | 10736-CV |
| Spike Protein | P.1.8 L18F, T20N, P26S, D138Y, T470N, E484K, N501Y, D614G, H655Y, P681R, T1027I, V1176F | HEK293 | GCN4-IZ, His | 11046-CV |
| Spike Protein | P.2 E484K, D614G, V1176F | HEK293 | GCN4-IZ, His | 11108-CV |
| Spike Protein | P.3 L141del, G142del, V143del, E484K, N501Y, D614G, P681H, E1092K, H1101Y, V1176F | HEK293 | GCN4-IZ, His | 10855-CV |
| Spike Protein | R.1.S W152L, E484K, D614G, G769V, R682S, R685S, K986P, V987P | HEK293 | GCN4-IZ, His | 11026-CV |
| S1 Subunit | A222V | HEK293 | His | 10725-CV |
| S1 Subunit | D614G | HEK293 | His | 10609-CV |
| CHO | His | 10618-CV | ||
| S1 Subunit | 20A.EU1 A222V, D614G | HEK293 | His | 10768-CV |
| S1 Subunit | 20A.EU2 S477N, D614G | HEK293 | His | 10780-CV |
| S1 Subunit | CAL.20C W152C, L452R, D614G | HEK293 | His | 10779-CV |
| S1 Subunit | 20C-US D614G, Q677H | HEK293 | His | 10778-CV |
| 20C-US D614G, Q677P | HEK293 | His | 10822-CV | |
| Spike RBD | Mu Variant B.1.621 R346K, E484K, N501Y | HEK293 | His | 10897-CV |
| Mu Variant B.1.621 R346K, K417N, E484K, N501Y | HEK293 | His | 10981-CV | |
| C.36.3 R346S, L452R | HEK293 | His | 10881-CV | |
| V367F | HEK293 | His | 10626-CV | |
| V367F, E484K | HEK293 | His | 10825-CV | |
| E406W | HEK293 | His | 10793-CV | |
| K417E | HEK293 | His | 10816-CV | |
| Delta Plus AY.1/AY.2 K417N, K452R, T478K | HEK293 | His | 10905-CV | |
| P.1.8 K417T, T470N, E484K, N501Y | HEK293 | His | 11036-CV | |
| N439K | HEK293 | His | 10714-CV | |
| AV.1 N439K, E484K | HEK293 | His | 10882-CV | |
| N440D | HEK293 | His | 10823-CV | |
| K444Q | HEK293 | His | 10814-CV | |
| V445A | HEK293 | His | 10819-CV | |
| B.1.630 L452R, T478R, E484Q | HEK293 | His | 11047-CV | |
| Lambda Variant C.37 K462Q, F490S | HEK293 | His | 10880-CV | |
| HEK293 | His, Avi-tag | AVI10880 | ||
| G446I | HEK293 | His | 10810-CV | |
| G446V | HEK293 | His | 10809-CV | |
| C.1.2 Y449H, E484K, N501Y | HEK293 | His | 10997-CV | |
| L452R | HEK293 | His | 10787-CV | |
| Y453F | HEK293 | His | 10744-CV | |
| Fc | 10792-CV | |||
| L455F | HEK293 | His | 10817-CV | |
| A475V | HEK293 | His | 10813-CV | |
| G476S | HEK293 | His | 10627-CV | |
| S477N | HEK293 | His | 10713-CV | |
| B.1.620 S477N, E484K | HEK293 | His | 10907-CV | |
| T478K | HEK293 | His | 10875-CV | |
B.1.640 346S, N394S, Y449N, F490R, N501Y | HEK293 | His | 11077-CV | |
| B.1.324.1 E484K, S494P, N501Y | HEK293 | His | 10830-CV | |
| F486I | HEK293 | His | 10790-CV | |
| F486V | HEK293 | His | 10812-CV | |
| Y489H | HEK293 | His | 10811-CV | |
| F490S | HEK293 | His | 10815-CV | |
| Q493K | HEK293 | His | 10791-CV | |
| S494P | HEK293 | His | 10789-CV | |
| V483A | HEK293 | His | 10628-CV | |
R&D Systems Spike Proteins Beat the Competition!
Our Spike Proteins exhibit higher binding activity to ACE-2 with better purity
SARS-CoV-2 Spike Protein
ELISA – Binding Activity
R&D Systems Recombinant SARS-CoV-2 Spike (10549-CV) binds Recombinant Human ACE-2 (933-ZN) in a functional ELISA. The binding activity is approximately 4-fold greater than a top competitor’s Spike protein (full ectodomain).
SDS-PAGE
SDS-PAGE of 1 µg of R&D Systems Recombinant SARS-CoV-2 Spike (10549-CV) or a competitor’s Spike protein were run under reducing or non-reducing conditions and visualized by silver staining. The R&D Systems Spike protein runs as a single band compared to the competition.
SARS-CoV-2 Spike RBD Protein
ELISA – Binding Activity
R&D Systems Recombinant SARS-CoV-2 Spike RBD (10500-CV) binds Recombinant Human ACE-2 (10544-ZN) in a functional ELISA. The binding activity is approximately 3-fold greater than a top competitor’s Spike RBD protein.
SDS-PAGE
SDS-PAGE of 1 µg of R&D Systems Recombinant SARS-CoV-2 Spike RBD (10500-CV) or a competitor’s Spike RBD protein were run under reducing or non-reducing conditions and visualized by silver staining. The R&D Systems Spike protein runs as a sharper, more definitive band than the competitor’s Spike RBD protein.
Nucleocapsid, NSP, and M Proteins
| Protein | Source | Tag | Catalog # | Bioactivity |
|---|---|---|---|---|
| SARS-CoV-2 Nucleocapsid Protein | Sf21 | His | 10474-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| Biotin, His | BT10474 | |||
| SARS-CoV-2 Nucleocapsid Protein (T205I) | Sf21 | His | 11033-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| SARS-CoV-2 Nucleocapsid Protein (R203K, G204R) | Sf21 | His | 10898-CV | Bioactivity not tested, >90% pure by SDS-PAGE |
| SARS-CoV-2 B.1.1.529 Nucleocapsid Protein | Sf21 | His | 11099-CV | Bioactivity not tested, >85% pure by SDS-PAGE |
| SARS-CoV-2 BA.2 Nucleocapsid Protein | Sf21 | His | 11182-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| SARS-CoV-2 B.1.1.7 Nucleocapsid Protein | Sf21 | His | 11001-CV | Bioactivity not tested, >90% pure by SDS-PAGE |
| SARS-CoV-2 B.1.2 Nucleocapsid Protein | Sf21 | His | 11000-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| SARS-CoV-2 B.1.2 (+D399N) Nucleocapsid Protein | Sf21 | His | 11216-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| SARS-CoV-2 B.1.617.2 Nucleocapsid Protein | Sf21 | His | 10999-CV | Bioactivity not tested, >90% pure by SDS-PAGE |
| SARS-CoV-2 P.1 Nucleocapsid Protein | Sf21 | His | 11002-CV | Bioactivity not tested, >90% pure by SDS-PAGE |
| SARS-CoV-2 P.2 Nucleocapsid Protein | Sf21 | His | 11062-CV | Bioactivity not tested, >90% pure by SDS-PAGE |
| SARS-CoV Nucleocapsid Protein | Sf21 | His | 10710-CV | Bioactivity not tested, >85% pure by SDS-PAGE |
| MERS-CoV Nucleocapsid Protein | Sf21 | His | 10521-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| HCoV-OC43 Nucleocapsid Protein | Sf21 | His | 10709-CVB | Bioactivity not tested, >90% pure by SDS-PAGE |
| HCoV-229E Nucleocapsid Protein | Sf21 | His | 10708-CV | Bioactivity not tested, >90% pure by SDS-PAGE |
| SARS-CoV-2 NSP1 | E. coli | His | 10666-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| SARS-CoV-2 NSP7 | E. coli | His | 10632-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| SARS-CoV-2 NSP8 | E. coli | His | 10633-CV | Bioactivity not tested, >90% pure by SDS-PAGE |
| SARS-CoV-2 NSP9 | E. coli | His | 10631-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| SARS-CoV-2 NSP10 | E. coli | His | 10630-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| SARS-CoV-2 NSP12 | Sf21 | His | 10686-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| SARS-CoV-2 NSP14 | E. coli | His | 10667-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| SARS-CoV-2 NSP16/10 Complex | E. coli | His | 10634-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| SARS-CoV-2 ORF-7a | CHO | Fc | 10668-CV | Bioactivity not tested, >90% pure by SDS-PAGE |
| SARS-CoV-2 Membrane (M) Protein | CHO | Fc | 10690-CV | Bioactivity not tested, >95% pure by SDS-PAGE |
| Protein | Species | Source | Tag | Catalog # | Bioactivity |
|---|---|---|---|---|---|
| SARS-CoV-2 Papain-like Protease | SARS-CoV-2 | E. coli | GST | E-611 | Cleaves Human ISG15 (Catalog # UL-553) Cleaves Ubiquitin-Rhodamine 110 (Catalog # U-555) |
| SARS Virus Papain-like Protease | SARS-CoV | E. coli | No tag | E-610 | |
| MERS-CoV Papain-like Protease | MERS-CoV | E. coli | No tag | E-609 | |
| SARS-CoV-2 3CL Protease | SARS-CoV-2 | E. coli | No tag | E-720 | Cleaves SARS CoV-2 3CL Protease Substrate, Rh110-conjugated (Catalog # S-720) |
| SARS-CoV 3CL Protease | SARS-CoV | E. coli | No tag | E-718 | |
| MERS-CoV 3CL Protease | MERS-CoV | E. coli | No tag | E-719 |
Receptor Recognition
Coronavirus binding to a cell surface receptor is a key mechanism of infection and a major focus of therapeutic research. Using proteins that are bioactive and have the correct conformation is critical for binding and drug development studies. Every protein listed below is QC tested for bioactivity and lot-to-lot consistency.
| Protein | Species | Source | Tag | Catalog # | Bioactivity |
|---|---|---|---|---|---|
| ACE-2 | Human | NS0 | His | 933-ZN | Binds SARS-CoV-2 S Protein RBD (10499-CV) |
| CHO | Fc | 10544-ZN | |||
| Mouse | CHO | His | 3437-ZN | Cleaves the fluorogenic peptide substrate, Mca-YVADAPK(Dnp)-OH (Catalog # ES007) | |
| Rat | NS0 | His | 4516-ZN | ||
| Pig | HEK293 | His | 10545-ZN | ||
| Dog | HEK293 | His | 10566-ZN | ||
| Chicken | HEK293 | His | 10592-ZN | ||
| Ferret | HEK293 | His | 10635-ZN | ||
| Cyno | NS0 | His | 10619-ZN | Binds SARS-CoV-2 S Protein RBD (10499-CV) | |
| Hamster | HEK293 | His | 10578-ZN | ||
| Biotinylated ACE-2 | Human | CHO | Avi-tag, His | AVI10579 | Binds SARS-CoV-2 S Protein RBD (10499-CV) |
| CHO | Avi-tag, Fc | AVI10544 | |||
| NS0 | His | BT933 | |||
| CHO | Fc | BT10544 | |||
| Alexa Fluor® ACE-2 | Human | NS0 | Alexa Fluor® 488, His | AFG933 | |
| NS0 | Alexa Fluor® 647, His | AFR933 | |||
| DPPIV | Human | NS0 | His | 9168-SE | Cleaves the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC) |
| Mouse | NS0 | His | 954-SE | ||
| Cyno | HEK293 | His | 9637-SE | ||
| Aminopeptidase N/CD13 | Human | NS0 | His | 3815-ZN | Cleaves the fluorogenic peptide substrate, Ala-7-amido-4-methylcoumarin (Ala-AMC) |
| Mouse | NS0 | His | 2335-ZN | ||
| CEACAM-1 | Human | NS0 | His | 2244-CM | Inhibits IL-2 secretion by T cells |
| LY6E | Human | HEK293 | Fc | 9970-L6 | Inhibits IFN-gamma and IL-2 secretion by T cells |
| EMMPRIN/CD147 | Human | NS0 | Fc, His | 972-EMN | Induces active MMP-1 secretion by NHLF human normal lung fibroblasts |
| Mouse | NS0 | His | 772-EM | ||
| Neuropilin-1 | Human | NS0 | His | 3870-N1 | Binds VEGF 165 |
| Mouse | NS0 | His | 5994-N1 | ||
| Rat | NS0 | Fc, His | 566-NNS | ||
| Rat | Sf21 | Fc, His | 566-N1 |
Host Cell Proteases
Host cell proteases are involved in coronavirus protein processing and activation. All enzymes listed are bioactive and QC tested to ensure consistency and activity.
| Protein | Species | Source | Tag | Catalog # | Bioactivity |
|---|---|---|---|---|---|
| Cathepsin B | Human | NS0 | His | 953-CY | Cleaves the fluorogenic peptide substrate Z-LR-AMC (Catalog # ES008) |
| Mouse | NS0 | His | 965-CY | ||
| Cathepsin L | Human | NS0 | His | 952-CY | Cleaves the fluorogenic peptide substrate Z-LR-AMC (Catalog # ES008) |
| Mouse | NS0 | His | 1515-CY | ||
| Furin | Human | NS0 | His | 1503-SE | Cleaves the fluorogenic peptide substrate pERTKR-AMC (Catalog # ES013) |
| Mouse | CHO | His | 6450-SE | ||
| Elastase/ELA2 | Human | CHO | His | 9167-SE | Cleaves the fluorogenic peptide substrate, MeOSuc-Ala-Ala-Pro-Val-7-amido-4-methylcoumarin (MeOSuc-AAPV-AMC |
| Mouse | NS0 | His | 4517-SE | ||
| Alexa Fluor is a registered trademark of Molecular Probes, Inc., Eugene, OR. | |||||
Find More Tools for Coronavirus Research
Browse our complete collection of products for SARS-CoV-2 research. From antibodies and assay kits to cell culture products and small molecules, we have the tools that you need to advance your SARS-CoV-2 research.
Custom Protein Services
Are you looking for something unique? Contact our Custom Protein Team to see how you can leverage over 30 years of protein development experience to meet your needs.
Bulk Proteins
Contact us and see how much you can save by buying in bulk. Supply agreements available. Contact us to request a quote.
Coronavirus Protein FAQs and Videos
Find out the answers to some of your frequently asked questions about our coronavirus proteins.
Do you have UK, South African, and Brazilian Variant spike protein mutants?
Yes, we offer multiple mutant spike proteins for the SARS-CoV-2 UK, South African, and Brazilian variants as well as many more. There are over 30 spike protein mutants to choose from.
Do you have an active recombinant SARS-CoV-2 Spike protein?
Yes, we offer SARS-CoV-2 active trimer proteins capable of binding to ACE-2. We also have spike subunits spike RBD proteins, and a chimeric spike-Fc fusion protein. Bulk and custom options are also available.
How may I assess the bioactivity of your proteins?
ELISA or SPR binding assays are currently the best option for bioactivity testing of Spike, S1, RBD, and ACE2. Most researchers will be using these proteins in binding assays, as such we have focused our in-house validation on that application. Low nanomolar binding for most of the Spike, S1, RBD in assays with ACE2 is currently regarded as the gold standard.
What is the difference between the full length ectodomain SARS-CoV-2 Spike (Active Trimer) and SARS-CoV-2 Spike (GCN4-IZ)?
The only difference between the two proteins is presence or lack of the GCN4-IZ domain. The full ectodomain in both proteins is the same sequence (Val16-Lys1211), however both Active Trimer and GCN4-IZ Spike proteins contain the endogenous HR1/HR2 trimerization domains. The SARS-CoV-2 Spike (GCN4-IZ) also includes an ectopic GCN4-IZ (Isoleucine Zipper) trimerization domain in addition to the natural HR1/HR2 trimerization motifs We made versions of Spike protein both with and without this additional GCN4-IZ motif in case the endogenous HR1/HR2 domains were not sufficient to form trimers when these spike proteins were made as recombinant proteins.
The SARS-CoV-2 Active Trimer products made in CHO and HEK293 cells are true trimers when analyzed by Size Exclusion Chromatography (SEC) analysis, demonstrating that the natural HR1/HR2 motifs are sufficient to form Spike trimers. Addition of the GCN4-IZ domain results in trimeric species and some slightly more oligomerized species in SEC analysis resulting in a more active trimer protein when used as a ligand with ACE2 proteins in ELISAs.
Why are there mutations in the full-length spike ectodomain proteins?
In the SARS-CoV-2 Spike Protein, the two mutations K986P and V987P are the corresponding mutations to K968P and V969P in the SARS-CoV Spike Protein, which promote the prefusion conformation (Kirchdoerfer et al. 2018). Two additional mutations in the SARS-CoV-2 Spike Protein R682S and R685S eliminate a furin protease cleavage site, making the Spike Protein resistant to furin cleavage.
Do you have an ACE-2 recombinant protein?
Yes, we have several ACE-2 proteins from different species including human, mouse, rat, hamster, and pig. These have been raised in HEK293, CHO, or NS0 host expression systems. We also have biotinylated versions of human ACE-2.
What is the difference in ACE-2 binding affinity of the glycosylated Spike protein and non-glycosylated Spike protein?
Glycosylation of the SAS-CoV-2 Spike RBD protein does not appear to affect its binding affinity to ACE-2. However, it is an important consideration when using these spike proteins as antigen to generate relevant blocking antibodies. In addition, researchers may want to consider glycosylation if using the spike proteins in serological diagnostic assays such as antigen-down ELISAs or lateral flow tests.
Which of the COVID-19 related proteases do you supply?
We have SARS and SARS-CoV-2 virus Papain-like Protease, and the 3CL protease. We also have the related MERS-COV Papain like protease, and its respective 3CL protease.
Read Article: Key Protease Targets for COVID-19
What is the difference between SARS CoV-2 proteins made in different source cells such as HEK293 and CHO?
SARS CoV-2 proteins can be highly glycosylated. When made in eukaryotic cell types such as CHO, HEK293, Sf21, or Tn5, this glycosylation pattern can differ depending on the cell type used. Antibodies made using these proteins might recognize cell type-specific glycan epitopes. In addition, glycans can affect receptor binding interactions, and proteins from a given source cell may work better in your specific assay.
Read Application Note: Glycosylation of the receptor binding domain of COVID-19 virus spike protein.
Can your proteins be used in serological assays and release testing assays?
Yes, we have maximized yields to meet the large mass demands required of serological assays and quality control release testing assays. In addition, we have data over multiple lots that demonstrate consistency in our manufacturing process.
If you would like to easily measure human ACE-2 levels by ELISA, our ACE-2 DuoSet® ELISA kit is designed and validated to deliver you the matched antibody pair, protein controls, and detection reagents you need to quantify natural or recombinant ACE-2. A Quantikine ELISA is also in development.
Please contact us for details on specific products and additional data.
Can you synthesize me a COVID-19 related protein conjugated to my fluorophore of choice?
Yes, we are happy to help with custom conjugation requests. We can either start with one of our existing catalog proteins, or custom synthesize a protein and conjugate it to your desired fluorophore.
Can you synthesize the pro form of IL-1F7b as a treatment for the COVID-19 hyperinflammatory response?
Yes. We can produce custom research-grade proteins suitable for proof-of-concept studies in vitro and in vivo in animal models. We can also produce GMP-compliant proteins for ex vivo use. Our products are not pharmaceutical grade and are not suitable direct injection into human patients.
Do you have a reliable and accurate serological assay for COVID-19?
Bio-Techne has partnered with Kantaro Biosciences to develop, scale, manufacture, and distribute an antibody test utilizing the Mount Sinai assay as the underlying technology. Kit production capacity is expected to enable laboratories to conduct in excess of 10 million tests.
This IgG antibody test kit is an enzyme-linked immunosorbent assay or ELISA, designed to measure the presence or absence of anti-SARS-CoV-2 antibodies in addition to measuring the titer (level) of antibodies in a sample. It utilizes two virus antigens, the full-length Spike protein, and its Receptor Binding Domain, which is necessary for viral cell entry and is potentially linked with neutralization. The test kit will use a simple patient blood draw and is designed to be easily run by any laboratory in the world without costly proprietary equipment.
Other resources
- Recombinant Proteins
- Additional Products for SARS-CoV-2 Research and Detection
- VersaClone cDNA Clones for Coronavirus Research
- Article: ACE-2: The Receptor for SARS-CoV-2
- Significant Events in the History of Virology Poster
- Virus Detection and Induction of Anti-Viral Signaling Pathways by RIG-I-like Receptors
- Infectious Diseases Research Area page
About Coronavirus Proteins
COVID-19 research and drug development speed along at an unprecedented pace as the scientific community searches for a cure. At R&D Systems, we understand the importance of quality recombinant proteins and enzymes with documented bioactivity and consistent performance for studying SARS-CoV-2 and other coronaviruses. We offer a range of different Spike RBD, S1 subunit, S2 subunit, and Spike full ectodomain proteins, as well as bioactive Papain-like proteases and 3CL proteases. With over 95% purity, the SARS-CoV-2 Nucleocapsid protein is an ideal antigen. Trusted for over 35 years, R&D Systems is the leading provider of recombinant proteins to the life science community.
Spike Protein
The Coronavirus Spike protein (S Protein) is one of four major structural proteins covering the surface of each virion. The Spike protein is a highly glycosylated, type I transmembrane protein responsible for host cell entry. Structurally, there are two domains, S1 and S2, that play major roles in receptor binding and membrane fusion. Within the N-terminal S1 domain is the receptor binding domain (Spike RBD protein). The Spike RBD binds to the host cell and initiates viral infection. The SARS-CoV-2 Spike RBD tightly associates with human ACE-2. Once the Spike S1 domain binds to its host receptor, conformational changes occur in the Spike S2 domain allowing for membrane attachment and eventually transfer of the nucleocapsid into the cell. Because of its essential role during Coronavirus infection, the Spike protein is major therapeutic target.
Nucleocapsid Protein
The Coronavirus Nucleocapsid protein (N Protein) is a multifunctional RNA-binding protein required for viral RNA transcription, replication, and packaging. The Nucleocapsid protein consists of three domains, an N-terminal RNA-binding domain, a central intrinsically disordered region, followed by a C-terminal dimerization domain. The RNA-binding domain contains multiple positively charged binding surfaces that form charged interactions with RNA promoting its helical arrangement. The Nucleocapsid protein is highly antigenic making it an attractive target for vaccine development and serological assays.
Papain-like Protease
The Coronavirus Papain-like protease (PLPro) is one of several nonstructural proteins (nsps) and along with 3CL Protease, is responsible for processing of viral proteins into functional, mature subunits during maturation. For example, PLPro cleaves a site at the amino-terminal end of the viral replicase region. In addition to its role in viral protein maturation, Papain-like protease exhibits both a deubiquitinating and deISG15ylating activity. In vivo, this protease antagonizes innate immunity by acting on IFN beta and NF- kappa B signaling pathways. Purified PLPro is used in vitro with polyubiquitin substrates demonstrating a strong preference for K48 linkages.
3CL Protease
The Coronavirus 3CL protease (3CLpro) is the other main protease in addition to the Papain-like protease and is required for processing of viral polypeptides into distinct, functional proteins. The SARS-CoV-2 3CL Protease is a C30-type cysteine protease located within the non-structural proteins 3 (NS3) region of the viral polypeptide. Analysis of the Coronavirus genome reveals at least 11 sites of cleavage for the 3CL Protease, many containing the amino acid sequence LQ[S/A/G]. In addition to the Papain-Like Protease, 3CLpro presents a promising therapeutic target for COVID-19. One attractive advantage of 3CLpro is that no human proteases are known to have a similar cleavage specificity making inhibitors of 3CLpro unlikely to cause mechanism-based toxicity.
Featured Content
NEW! SARS-CoV-2 Variant Inhibitor Screening Kit
Screen samples for Spike blocking antibodies. Wild Type, Alpha, Beta, Gamma, and Delta Spike Variants. All in one kit!
White Paper: Levels and Neutralizing Ability of Antibodies in COVID-19 Patients and Vaccinated Individuals
Examining how SARS-CoV-2 variants affect antibody blocking ability in COVID-19-exposed and vaccinated individuals.
Custom Protein Libraries
Select from over 5000 R&D Systems proteins delivered in a 96-well plate, ideal for high-throughput screening
COVID-19 Symposium Golden Ticket Winner
Meet the recipient of Bio-Techne’s COVID-19 Virtual Symposium Golden Ticket, Arif Istiaq, a Ph.D. student at Kyushu University
Application Note: Glycosylation of the Receptor Binding Domain of COVID-19 Virus Spike Protein
R&D Systems examines the impact of expression system on spike RBD protein glycosylation
Coronavirus Protein FAQs
Our technical team answers some of your frequently asked questions about our coronavirus proteins.
Tools to Support Coronavirus Research Brochure
Download our new brochure to learn more about our large portfolio of tools for SARS-CoV-2 research.
Immunoassays For COVID-19 Research
Get the assays you need for fast, accurate detection of key cytokines and antibodies triggered by viral infections like COVID-19